Pinned Tweet
Some hospitals and clinics are running up the score on 340B markups, generating billions in profits with no requirement that patients benefit.
Patients lose. Hospitals win.
It's time to fix 340B.
ow.ly/fUEq50ZLtv5
AI is changing the life sciences industry.
At @axios Live, @LukeBernstein, President and CEO of @PAChamber, spoke about the crossroads we’re at today ⬇️
𝐇𝐞𝐚𝐥𝐭𝐡 𝐢𝐧𝐬𝐮𝐫𝐚𝐧𝐜𝐞 𝐜𝐨𝐬𝐭𝐬 𝐚𝐫𝐞 𝐭𝐨𝐩 𝐯𝐨𝐭𝐞𝐫 𝐡𝐞𝐚𝐥𝐭𝐡 𝐜𝐚𝐫𝐞 𝐩𝐫𝐢𝐨𝐫𝐢𝐭𝐢𝐞𝐬. When voters were asked to identify their two most important health care issues, insurance-related concerns were at the top of their list.
💵34% selected health insurance-related out-of-pocket costs such as copays, deductibles and coinsurance.
☂️30% selected health insurance premiums.
🏥23% selected the cost of hospital services.
💊23% selected the cost of prescription medicines.
ow.ly/S3Gy50ZZH9n
In 2025, hospitals, clinics and their for profit-partners profited $142 BILLION from the 340B program, begging the question – where is the money going?
A rebate-based rapid verification model would bring greater transparency and accountability through basic claims-level verification while protecting patient access.
Find out at PhRMA.org/340B
The 340B program started with good intentions, but years of explosive growth with almost no oversight have it out of control. In 2025, tax-exempt hospitals, clinics and their for-profit partners got $142 billion in profits with no requirement that patients benefit.
The result is higher prices and higher premiums for patients, taxpayers and employers. It's time to get 340B back on track.
You wouldn't pay a restaurant tab without seeing the bill, but that's how 340B works today with no verification and no transparency. A rebate model would modernize this program by adding long-overdue guardrails without disrupting patient access or safety net providers: phrma.org/blog/why-340b-need…
Science has come an incredibly long way in treating the world’s diseases, but science alone isn’t enough.
It takes smart policy to drive the innovation ecosystem we need in order to get treatments and cures into the hands of the patients who need them.
ow.ly/q9Rw50ZZ7MM
In just 15 days, voters will make their voices heard in the 2026 midterm elections – so what are their priorities when it comes to health care?
Well, health insurance costs like deductibles, copays and premiums rank highest in voters' health care priorities.
Hear more from a recent @votersforcures poll: ow.ly/jyVx50ZZ1Xn
Vaccines keep us safe, but that’s not all. They deliver a strong return on investment by reducing health care costs, supporting workforce productivity and generating long-term economic value for America.
Learn more: ow.ly/AmJX50ZYIGT
Middlemen often become a one-stop obstacle shop. Why? They like pharmacies that can make them more money.
Find out more at PhRMA.org/AskYourPBM
Huntsville is quickly becoming one of the country’s next biotech hubs, and the momentum is only building as new manufacturing investment and a growing life sciences workforce take root in the Rocket City. 🚀
PhRMA joins @axios today to hear more about how they’re doing it: ow.ly/AcKE50ZY1kE
Huntsville’s biotech momentum was on full display at @Axios’ Beyond the Breakthrough event, where PhRMA’s Alex Schriver and @EliLillyandCo’s Graciela Romero made the case that when companies and cities invest in innovation, everyone benefits.
Thanks for having us, @axios!
Today, @Merck inaugurated its state-of-the-art ADVANCE research facility on its West Point, Pennsylvania, campus.
Joined by Governor Shapiro, the ceremony signals a new chapter in global scientific discovery and builds on the company’s presence in Pennsylvania, bringing new jobs and opportunities to the Commonwealth and new research and breakthroughs for patients.
ow.ly/Fc1K50ZXNMj
About half of U.S. children are eligible for the Vaccines for Children program, which provides recommended vaccines at no cost to eligible families.
In 2024, the program distributed 73 million vaccine doses.
As respiratory season begins, protecting vaccine access matters: ow.ly/usOc50ZXMjc
Bob uses his own fight with cancer to advocate for smart policies that enable the medical breakthroughs patients are waiting on.
Tune in tomorrow to @axios Live in 📍Huntsville, AL: ow.ly/MaST50ZXHcS
350,000+ jobs. 1,500+ facilities. $500B invested. Biopharmaceutical’s U.S. manufacturing buildout depends on strong IP protections. This #IPMonth and #ManufacturingMonth, Congress can reaffirm its commitment to protecting that system.
Read more: ow.ly/G45150ZXhg0
People like Anton put in the time and effort to push for new medicines for patients. American policies make sure those new medicines are available here, and fast. That leadership is worth protecting.
AmericaCures.com